How to optimize the use of adjuvant pembrolizumab in renal cell carcinoma: which patients benefit th...
How to optimize the use of adjuvant pembrolizumab in renal cell carcinoma: which patients benefit the most?
About this item
Full title
Author / Creator
Fallara, Giuseppe , Larcher, Alessandro , Rosiello, Giuseppe , Raggi, Daniele , Marandino, Laura , Martini, Alberto , Basile, Giuseppe , Colandrea, Gianmarco , Cignoli, Daniele , Belladelli, Federico , Re, Chiara , Musso, Giacomo , Cei, Francesco , Bertini, Roberto , Briganti, Alberto , Salonia, Andrea , Montorsi, Francesco , Necchi, Andrea and Capitanio, Umberto
Publisher
Berlin/Heidelberg: Springer Berlin Heidelberg
Journal title
Language
English
Formats
Publication information
Publisher
Berlin/Heidelberg: Springer Berlin Heidelberg
Subjects
More information
Scope and Contents
Contents
Purpose
The KEYNOTE-564 trial showed improved disease-free survival (DFS) for patients with high-risk renal cell carcinoma (RCC) receiving adjuvant pembrolizumab as compared to placebo. However, if systematically administered to all high-risk patients, it might lead to the overtreatment in a non-negligible proportion of patient. Therefore, we ai...
Alternative Titles
Full title
How to optimize the use of adjuvant pembrolizumab in renal cell carcinoma: which patients benefit the most?
Authors, Artists and Contributors
Author / Creator
Larcher, Alessandro
Rosiello, Giuseppe
Raggi, Daniele
Marandino, Laura
Martini, Alberto
Basile, Giuseppe
Colandrea, Gianmarco
Cignoli, Daniele
Belladelli, Federico
Re, Chiara
Musso, Giacomo
Cei, Francesco
Bertini, Roberto
Briganti, Alberto
Salonia, Andrea
Montorsi, Francesco
Necchi, Andrea
Capitanio, Umberto
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2729996678
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2729996678
Other Identifiers
ISSN
1433-8726,0724-4983
E-ISSN
1433-8726
DOI
10.1007/s00345-022-04153-6
